Health Care • Medicinal Chemicals and Botanical Products
$1.11 ▼ -0.05
(-4.31%)
MKT CAP: $6.9M • VOL: 38.0K
52W L $1 52W H $5
NAII // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $129.9M | $113.8M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $9.3M | $6.9M | — |
| Gross Margin % | 7.2% | 6.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.7M | -$8.5M | $4.7M |
| Operating Margin % | -6.7% | -7.5% | — |
| Net Income (GAAP) | -$13.6M | -$7.2M | $2.5M |
| EBITDA (Normalized) | -$5.8M | -$6.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $5.9M | -$1.5M | $7.0M |
| Capital Expenditures (CapEx) | $3.6M | $3.0M | — |
| Free Cash Flow (FCF) | $2.3M | -$4.5M | $7.0M |
| FCF Margin % | 1.8% | -4.0% | — |
| Return on Invested Capital (ROIC %) | -10.8% | -9.6% | — |
| Cash & Short-Term Equivalents | $3.8M | $8.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $67.0M | $79.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NAII.